145Low toxicity and efficacy of 153-samarium-EDTMP/MELPHALAN as a conditioning regimen for secondary acute myelogenous leukemia
نویسندگان
چکیده
منابع مشابه
Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia
Optimal conditioning therapy for hematopoietic cell transplantation (HCT) in acute myelogenous leukemia (AML) remains undefined. We retrospectively compared outcomes of a consecutive series of 51 AML patients treated with oral busulfan (1 mg/kg every 6 hours for 4 days) and cyclophosphamide (60 mg/kg IV × 2 days) - (Bu/Cy) with 100 consecutive AML patients treated with pharmacokinetic targeted ...
متن کاملevaluation of chemotherapy toxicity in acute lymphoblastic and myelogenous leukemia
background and aims : adverse drug reactions (adrs) are one of the major leading causes of death in the world. this study was designed and conducted because of the importance of adverse events in the cancer treatment setting and regarding this issue there is no study exploring adverse reactions of acute hematologic malignancy chemotherapy in iranian population. methods : this was a prospective,...
متن کاملFamilial Acute Myelogenous Leukemia: Report of Three Cases
Acute myelogenous leukemia (AML) is a hematological malignancy, which accounts for about 15-25% of childhood's leukemia. Genetic factor is one of the most important predisposing elements in childhood acute leukemia, especially AML. In this case report, a rare presentation of familial AML is presented in three monozygotic triplets. Two were 10 months old, and the other one was 16 months old at p...
متن کاملAcute Myelogenous Leukemia
Acute myeloid leukemia is not a single disease but a group of neoplastic disorders. The malignant cells gradually replace, and inhibit the growth and maturation of, normal erythroid, myeloid, and megakaryocytic precursors. Included among the names for this condition are acute myelogenous leukemia, acute myelocytic leukemia, acute myeloid leukemia, acute myeloblastic leukemia, acute granulocytic...
متن کاملAcute Myelogenous Leukemia
Documented central nervous system (CNS) involvement in acute myelogenous leukemia (AML), unlike acute lymphocytic leukemia, is relatively uncommon [1 , 2] . CNS involvement in AML is reported to occur in 6%-17% of cases [1-4]. It is expected that improvements in therapy with increased frequency of remission and prolonged survival will lead to further increases in clinical CNS involvement in AML...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biology of Blood and Marrow Transplantation
سال: 2003
ISSN: 1083-8791
DOI: 10.1016/s1083-8791(03)80146-5